What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

What question did this study set out to answer?

To determine long-term treatment-free remission (TFR) rates after TKI discontinuation in a large cohort of Japanese patients with chronic myeloid leukemia.

December 8, 2025Blood

Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI

View Full Paper

Ask AI

Bookmark

Authors

SKShinya Kimura MSMasashi Sawa YSYoshio Saburi

Discussion

Member takes

Overview

Multicenter study showed 65.2% treatment-free remission in chronic myeloid leukemia patients after TKI discontinuation, indicating effective management.

Key Points

To determine long-term treatment-free remission (TFR) rates after TKI discontinuation in a large cohort of Japanese patients with chronic myeloid leukemia.
Multicenter observational study design with prospective and retrospective cohorts
Enrolled patients with major BCR::ABL1 positive chronic myeloid leukemia
Primary endpoint was TFR rate at 5 years, collected data until May 31, 2024
TFR rate at 60 months was 65.2% (95% CI: 59.6-70.6%)
87% of patients who resumed TKI therapy regaining major molecular response (MMR) after molecular relapse
No patients progressed to blast crisis

Cite This Study

Kimura et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e413 https://doi.org/10.1182/blood-2025-5545

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Five-year interim analysis of multi-institutional collaborative study for estimating the persistence of treatment free remission in chronic myeloid leukemia after stopping tyrosine kinase inhibitor in Japan: J-SKI

View Full Paper

Ask AI

Bookmark

Authors

SKShinya Kimura MSMasashi Sawa YSYoshio Saburi

Discussion

Member takes

Overview

Multicenter study showed 65.2% treatment-free remission in chronic myeloid leukemia patients after TKI discontinuation, indicating effective management.

Key Points

To determine long-term treatment-free remission (TFR) rates after TKI discontinuation in a large cohort of Japanese patients with chronic myeloid leukemia.
Multicenter observational study design with prospective and retrospective cohorts
Enrolled patients with major BCR::ABL1 positive chronic myeloid leukemia
Primary endpoint was TFR rate at 5 years, collected data until May 31, 2024
TFR rate at 60 months was 65.2% (95% CI: 59.6-70.6%)
87% of patients who resumed TKI therapy regaining major molecular response (MMR) after molecular relapse
No patients progressed to blast crisis

Cite This Study

Kimura et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e413 https://doi.org/10.1182/blood-2025-5545

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark